Facilitating effects of valproate on reconsolidation of fear extinction

Seoul National University Hospital0 个研究点目标入组 92 人开始时间: 待定最近更新: 2024年6月24日

试验速览

暂无简介。

•Participants provided with an explanation of the study and written consent.
•- Participants with uncorrected visual acuity of -8.0 to -2.0 diopters (no restrictions for corrected vision with glasses or lenses).
•- Participants not currently having administered any treatment medication and in physical health.

•- Carefully considered group of Biolamin Tablet: patients currently taking L-dopa, patients with hyperoxaluria, or pregnant or lactating women.
•- Individuals with hypersensitivity to polyvitamin (with vitamine B1, B2, B6, B12, C, or E)
•- Individulas not classified as healthy subjects through clinical examination.
•- Individuals with organic brain damage or a history of head and neck trauma.
•- Patients currently undergoing psychiatric treatment or with a psychiatric history.
•- Individuals anticipating surgery or procedures which could interfere the study procedures.
•- Carefully considered and contraindicated group of Promag Tablet: patients with liver disease or impairment, renal failure or low protein levels, blood clotting disorders or low platelet count, a history of bone marrow damage or potential patients, or currently pregnant or potentially pregnant women.
•- Individuals with a history of adverse reactions to valproate.
•- Individuals with difficulty in oral mication intake.
•- Researchers directly involved in the present clinical study, researchers' families, employees of the research institution, and their families.

发起方